about
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules,...
Read More
36.37
-1.63
(-4.29%)
579.9K
XNAS Volume
XNAS 18 Sep, 2026 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Pharvaris NV Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..